Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea have?
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea has 33 citations in the OpenAlex counts ScholarIQ stores.
When was Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea published?
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea has 2015 year in the ScholarIQ index.
What is the open-access status of Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea?
Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea has bronze oa status in the ScholarIQ index.
What is the DOI of Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea?
The DOI for Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea is on the source record.
What is the PMID of Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea?
The PMID for Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea is on the source record.
What is the OpenAlex record for Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea?
The OpenAlex for Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea is on the source record.